BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus...
ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus
ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus The...
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA...
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical...
Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses
Public Release
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO,...